Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

L Diamond

Showing results (961-970 of 1,028) with videos related to

Pageof 103
Sort By:
Blood Advances|June 17, 2026
Class 3 MAP2K1 mutations are associated with frequent relapse and multiple treatment lines in multi-system Langerhans cell histiocytosisKevin D Hofer, Claire Seydoux, Florian Angst, et al.
Plos Pathogens|May 30, 2009
Host cell factors in HIV replication: meta-analysis of genome-wide studiesFrederic D Bushman, Nirav Malani, Jason Fernandes, et al.
Neurology(R) Neuroimmunology & Neuroinflammation|October 23, 2025
Refractory Tumorous and Neurodegenerative Histiocytosis Treated With Intra-Arterial ChemotherapyAlexander Ramos, Andrew L A Garton, Jared Knopman, et al.
Environmental Science & Technology Letters|May 25, 2026
Scientists' statement on the chemical definition of PFASsGabriel Sigmund, Marta Venier, Marlene Ågerstrand, et al.
Cancers|November 6, 2020
The Contribution of MicroRNAs to the Inflammatory and Neoplastic Characteristics of Erdheim-Chester DiseaseRan Weissman, Eli L Diamond, Julien Haroche, et al.
ACS Chemical Biology|October 13, 2017
Discovery of a Distinct Chemical and Mechanistic Class of Allosteric HIV-1 Integrase Inhibitors with Antiretroviral ActivityChristine Burlein, Cheng Wang, Min Xu, et al.
Blood Neoplasia|June 2, 2025
Driver mutations in myeloid and lymphoid cells point to multipotent progenitor origin of diverse histiocytic neoplasmsAstrid G S van Halteren, Paul G Kemps, Jelske Forma-Borst, et al.
Lab on a Chip|March 15, 2024
Next generation microfluidics: fulfilling the promise of lab-on-a-chip technologiesUmut A Gurkan, David K Wood, Dorn Carranza, et al.
Lancet (London, England)|February 7, 2026
Switch to fixed-dose doravirine (100 mg) and islatravir (0·25 mg) once daily in virologically suppressed adults with HIV-1 on oral antiretroviral therapy: 48-week results of a phase 3, multicentre, randomised, open-label, non-inferiority trialChloe Orkin, Rosie Mngqibisa, Juan Diego Velez, et al.
Plos Pathogens|January 12, 2010
Temporal proteome and lipidome profiles reveal hepatitis C virus-associated reprogramming of hepatocellular metabolism and bioenergeticsDeborah L Diamond, Andrew J Syder, Jon M Jacobs, et al.
Pageof 103

Showing results (961-970 of 1,028) with videos related to

Sort By:
Pageof 103
Blood Advances|June 17, 2026
Class 3 MAP2K1 mutations are associated with frequent relapse and multiple treatment lines in multi-system Langerhans cell histiocytosisKevin D Hofer, Claire Seydoux, Florian Angst, et al.
Plos Pathogens|May 30, 2009
Host cell factors in HIV replication: meta-analysis of genome-wide studiesFrederic D Bushman, Nirav Malani, Jason Fernandes, et al.
Neurology(R) Neuroimmunology & Neuroinflammation|October 23, 2025
Refractory Tumorous and Neurodegenerative Histiocytosis Treated With Intra-Arterial ChemotherapyAlexander Ramos, Andrew L A Garton, Jared Knopman, et al.
Environmental Science & Technology Letters|May 25, 2026
Scientists' statement on the chemical definition of PFASsGabriel Sigmund, Marta Venier, Marlene Ågerstrand, et al.
Cancers|November 6, 2020
The Contribution of MicroRNAs to the Inflammatory and Neoplastic Characteristics of Erdheim-Chester DiseaseRan Weissman, Eli L Diamond, Julien Haroche, et al.
ACS Chemical Biology|October 13, 2017
Discovery of a Distinct Chemical and Mechanistic Class of Allosteric HIV-1 Integrase Inhibitors with Antiretroviral ActivityChristine Burlein, Cheng Wang, Min Xu, et al.
Blood Neoplasia|June 2, 2025
Driver mutations in myeloid and lymphoid cells point to multipotent progenitor origin of diverse histiocytic neoplasmsAstrid G S van Halteren, Paul G Kemps, Jelske Forma-Borst, et al.
Lab on a Chip|March 15, 2024
Next generation microfluidics: fulfilling the promise of lab-on-a-chip technologiesUmut A Gurkan, David K Wood, Dorn Carranza, et al.
Lancet (London, England)|February 7, 2026
Switch to fixed-dose doravirine (100 mg) and islatravir (0·25 mg) once daily in virologically suppressed adults with HIV-1 on oral antiretroviral therapy: 48-week results of a phase 3, multicentre, randomised, open-label, non-inferiority trialChloe Orkin, Rosie Mngqibisa, Juan Diego Velez, et al.
Plos Pathogens|January 12, 2010
Temporal proteome and lipidome profiles reveal hepatitis C virus-associated reprogramming of hepatocellular metabolism and bioenergeticsDeborah L Diamond, Andrew J Syder, Jon M Jacobs, et al.
Pageof 103